A First-in-Human Study of AV-001 in Healthy Subjects

Covid19 Clinical Trial

Official title: A Randomized, Double-blind, Placebo-controlled Phase 1 Single and Multiple-Dose Pharmacokinetic First-in-Human Study of AV-001 in Healthy Subjects

Status Completed

Clinical Trial Summary

Phase 1 randomized, double-blind, placebo-controlled single ascending dose (SAD) and multiple ascending dose (MAD) first-in-human study in healthy subjects. Safety and tolerability assessments will be conducted, and blood samples will be taken pre-dose and at several time points post-dose for pharmacokinetic (PK) and pharmacodynamics (PD) analysis.

Clinical Trial Description

In the SAD segment of the study, up to 4 ascending cohorts of 8 healthy subjects each will receive a single dose of study drug (AV-001 or placebo) in a sequential ascending manner. Planned doses may be adapted depending on emergent safety, tolerability and available PK data. Screening evaluations will occur from Day -28 to Day -2. Eligible subjects will be admitted to the clinical unit on Day -2. On Day 1, subjects will be randomized to AV-001 (6 subjects) or placebo (2 subjects) and receive a single dose of study drug. Subjects will be discharged on Day 2 after all post dose assessments have been completed and if there are no medical reasons for a longer stay in the clinical unit. An end of study visit will be conducted 7 to 10 days after Day 1 or at early termination. An initial sentinel group consisting of 1 subject receiving AV-001 and 1 subject receiving placebo will proceed for each cohort prior to treatment of the remainder of the cohort. After study drug administration to the sentinel group and an appropriate safety interval (at least 24 hours and per the discretion of the Principal Investigator (PI)), the remaining 5 subjects will receive a single dose of AV-001 and 1 subject will receive placebo administered in the same manner. PK blood samples will be collected at 15 time points relative to study drug dosing on Day 1. PD blood samples for will be collected at 6 time points on Day 1. In the MAD segment of the study, up to 2 ascending cohorts of 8 subjects each will receive once daily doses of study drug (AV-001 or placebo) for at least 7 days in a sequential ascending manner. Planned doses may be adapted and will be determined by the safety, tolerability and PK data from the SAD part of the study. Screening evaluations will occur from Day -28 to Day -2. Eligible subjects will be admitted to the clinical unit on Day -2. On Day 1, subjects will be randomized to AV-001 (6 subjects) or placebo (2 subjects). Subjects will receive once-daily doses of study drug from Day 1 through Day 7. Subjects will be discharged on Day 8 after all post dose assessments have been completed and if there are no medical reasons for a longer stay in the clinical unit. An end of study visit will be conducted 7 to 10 days after Day 7 or at early termination. PK blood samples will be collected at 15 time points relative to study drug dosing on Day 1 and Day 7 in addition to predose levels on Days 2 to 6. PD blood samples for will be collected at 6 time points on Day 1 and Day 7. ;

Related Conditions & MeSH terms

• ARDS
• Covid19
• Covid19-associated ARDS

• NCT number: NCT04737486
• Study type: Interventional
• Source: Vasomune Therapeutics, Inc.
• Status: Completed
• Phase: Phase 1
• Start date: December 16, 2020
• Completion date: March 10, 2021